{"ticker": {"uuid": "43fce935-d89d-4a60-883a-3eedb25e8674", "symbol": "SAN", "name": "Sanofi", "exchange": "PAR", "country": "FR", "sector": "Healthcare", "industry": "Drug Manufacturers - General"}, "articles": [{"title": "[Latest] Global Whey Protein Market Size/Share Worth USD 26.04 Billion by 2034 at a 7.56% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)", "summary": "Custom Market Insights [220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Whey Protein Market size & share revenue was valued at approximately USD 12.58 Billion in 2024 and is expected to reach USD 13.52 Billion in 2025 and is expected to reach around USD 26.04 Billion by 2034, at a CAGR of 7.56% between 2025 and 2034. The key market players listed in the report with their sales, revenues and strategies are Abbott, Alpavit, Arla Foods, Carbery Group, Davisco Foods International, Inc., Fonterra Co-operative Group Lt", "url": "https://finance.yahoo.com/markets/commodities/articles/latest-global-whey-protein-market-173000212.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-12T17:30:00+00:00", "published_display": "12 Aug 2026 17:30", "sentiment": "positive", "sentiment_pct": 61, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.295, "duplicate_count": 1, "topics": ["Dietary Supplements", "E Commerce", "Functional Foods", "Growth Rate", "Market Research Reports", "Sports Nutrition"]}, {"title": "InduPro Closes $77 Million Series B Financing and Doses First Patient in Phase 1 Study of Lead Oncology Program IDP-001", "summary": "IDP-001 is a bispecific antibody-drug conjugate targeting EGFR and a novel Tumor-Associated Proximity Antigen identified through InduPro's proximity-guided platform Phase 1 study is enrolling adults with advanced squamous non-small cell lung cancer and other solid tumors Financing led by The Column Group, with participation from Vida Ventures, MRL Ventures Fund, Emerson Collective (advised by Yosemite), Euclidean Capital, Solasta Ventures, Sanofi, and Eli Lilly and Company SEATTLE & CAMBRIDGE, Mass., August 12, 2026--(BUSINESS WIRE)--InduPro, Inc., a biotechnology company defining membrane pro", "url": "https://finance.yahoo.com/healthcare/articles/indupro-closes-77-million-series-113000456.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-12T11:30:00+00:00", "published_display": "12 Aug 2026 11:30", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.163, "duplicate_count": 1, "topics": ["Antibody Drug Conjugates", "Biotech", "Cancer", "Clinical Trials"]}, {"title": "Adagene Reports Six Months 2026 Financial Results and Provides Corporate Updates", "summary": "Adagene Inc. Randomized Phase 2 trial in microsatellite stable colorectal cancer (MSS CRC) ongoing, with results expected in 1H 2027; potential registration trial expected in 2027 once recommended dose regimen has been established Data reported at AACR from triple combination therapy in 1L hepatocellular carcinoma (HCC) and late-line MSS CRC highlights muzastotug's potential as a backbone combination treatment for multiple tumor types across all lines of therapy Initiated dosing in a global Phase 1/2 basket trial evaluating muzastotug in combination with a next-generation investigational IO ag", "url": "https://finance.yahoo.com/healthcare/articles/adagene-reports-six-months-2026-113000661.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-12T11:30:00+00:00", "published_display": "12 Aug 2026 11:30", "sentiment": "neutral", "sentiment_pct": 54, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.233, "duplicate_count": 1, "topics": ["Biotech", "Clinical Trials", "Financial Results", "Oncology", "Partnerships"]}, {"title": "Why the Amlitelimab Setback Isn\u2019t Enough to Sink Sanofi\u2019s Multi-Billion Dollar Engine", "summary": "It was reported on July 24 that Sanofi (NASDAQ:SNY) shares underperformed in European trading following the company's decision to drop the clinical development of its eczema candidate, amlitelimab, for moderate-to-severe atopic dermatitis. Rather than a fundamental breakdown, the move reflects an aggressive R&D pipeline review under CEO Bel\u00e9n Garijo, who chose to pull the plug after efficacy and safety data failed to support global regulatory submissions. For a mega-cap pharmaceutical giant like Sanofi, valued at more than $100 billion, abandoning a zero-revenue clinical trial asset is a neces", "url": "https://finance.yahoo.com/healthcare/articles/why-amlitelimab-setback-isn-t-232940996.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-10T23:29:40+00:00", "published_display": "10 Aug 2026 23:29", "sentiment": "positive", "sentiment_pct": 63, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.259, "duplicate_count": 1, "topics": ["Biotech", "Clinical Trials", "Earnings", "Earnings Report", "Fda Approval", "Institutional Investors"]}, {"title": "Nurix Therapeutics' STAT6 Degrader Likely to Receive Increased Recognition, RBC Says", "summary": "Nurix Therapeutics' (NRIX) STAT6 degrader NX-3911 is likely to receive increased recognition after advancing into clinical development under its collaboration with Sanofi (SNY), RBC Capital Markets said in a Monday research note.The investment firm said limited preclinical data Silver Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade now", "url": "https://finance.yahoo.com/healthcare/articles/nurix-therapeutics-apos-stat6-degrader-164414074.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-10T16:44:14+00:00", "published_display": "10 Aug 2026 16:44", "sentiment": "positive", "sentiment_pct": 61, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.153, "duplicate_count": 1, "topics": ["Clinical Trials", "Pharma"]}, {"title": "Novavax (NVAX) Is Up 8.6% After Beating Q2 Estimates And Expanding Big-Pharma Partnerships - What's Changed", "summary": "In early August 2026, Novavax reported Q2 2026 revenue of US$56.7 million, sharply lower than the prior year, and moved from net income to a net loss of US$53.39 million, translating into basic and diluted losses of US$0.32 per share from continuing operations. Alongside the weak year-on-year comparisons, Novavax beat analyst expectations for both revenue and earnings and highlighted progress on high-profile partnerships, including Sanofi and Pfizer, while also filing an US$82.47 million employee stock offering shelf registration. Now we'll examine how this mix of better-than-expected Q2 resul", "url": "https://finance.yahoo.com/healthcare/articles/novavax-nvax-8-6-beating-101004083.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-08T10:10:04+00:00", "published_display": "08 Aug 2026 10:10", "sentiment": "negative", "sentiment_pct": 24, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.122, "duplicate_count": 1, "topics": ["Dilution Risk", "Earnings", "Guidance", "Net Income", "Partnerships", "Share Price"]}], "by_tier": {"direct": [{"title": "[Latest] Global Whey Protein Market Size/Share Worth USD 26.04 Billion by 2034 at a 7.56% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)", "summary": "Custom Market Insights [220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Whey Protein Market size & share revenue was valued at approximately USD 12.58 Billion in 2024 and is expected to reach USD 13.52 Billion in 2025 and is expected to reach around USD 26.04 Billion by 2034, at a CAGR of 7.56% between 2025 and 2034. The key market players listed in the report with their sales, revenues and strategies are Abbott, Alpavit, Arla Foods, Carbery Group, Davisco Foods International, Inc., Fonterra Co-operative Group Lt", "url": "https://finance.yahoo.com/markets/commodities/articles/latest-global-whey-protein-market-173000212.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-12T17:30:00+00:00", "published_display": "12 Aug 2026 17:30", "sentiment": "positive", "sentiment_pct": 61, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.295, "duplicate_count": 1, "topics": ["Dietary Supplements", "E Commerce", "Functional Foods", "Growth Rate", "Market Research Reports", "Sports Nutrition"]}, {"title": "InduPro Closes $77 Million Series B Financing and Doses First Patient in Phase 1 Study of Lead Oncology Program IDP-001", "summary": "IDP-001 is a bispecific antibody-drug conjugate targeting EGFR and a novel Tumor-Associated Proximity Antigen identified through InduPro's proximity-guided platform Phase 1 study is enrolling adults with advanced squamous non-small cell lung cancer and other solid tumors Financing led by The Column Group, with participation from Vida Ventures, MRL Ventures Fund, Emerson Collective (advised by Yosemite), Euclidean Capital, Solasta Ventures, Sanofi, and Eli Lilly and Company SEATTLE & CAMBRIDGE, Mass., August 12, 2026--(BUSINESS WIRE)--InduPro, Inc., a biotechnology company defining membrane pro", "url": "https://finance.yahoo.com/healthcare/articles/indupro-closes-77-million-series-113000456.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-12T11:30:00+00:00", "published_display": "12 Aug 2026 11:30", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.163, "duplicate_count": 1, "topics": ["Antibody Drug Conjugates", "Biotech", "Cancer", "Clinical Trials"]}, {"title": "Adagene Reports Six Months 2026 Financial Results and Provides Corporate Updates", "summary": "Adagene Inc. Randomized Phase 2 trial in microsatellite stable colorectal cancer (MSS CRC) ongoing, with results expected in 1H 2027; potential registration trial expected in 2027 once recommended dose regimen has been established Data reported at AACR from triple combination therapy in 1L hepatocellular carcinoma (HCC) and late-line MSS CRC highlights muzastotug's potential as a backbone combination treatment for multiple tumor types across all lines of therapy Initiated dosing in a global Phase 1/2 basket trial evaluating muzastotug in combination with a next-generation investigational IO ag", "url": "https://finance.yahoo.com/healthcare/articles/adagene-reports-six-months-2026-113000661.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-12T11:30:00+00:00", "published_display": "12 Aug 2026 11:30", "sentiment": "neutral", "sentiment_pct": 54, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.233, "duplicate_count": 1, "topics": ["Biotech", "Clinical Trials", "Financial Results", "Oncology", "Partnerships"]}, {"title": "Why the Amlitelimab Setback Isn\u2019t Enough to Sink Sanofi\u2019s Multi-Billion Dollar Engine", "summary": "It was reported on July 24 that Sanofi (NASDAQ:SNY) shares underperformed in European trading following the company's decision to drop the clinical development of its eczema candidate, amlitelimab, for moderate-to-severe atopic dermatitis. Rather than a fundamental breakdown, the move reflects an aggressive R&D pipeline review under CEO Bel\u00e9n Garijo, who chose to pull the plug after efficacy and safety data failed to support global regulatory submissions. For a mega-cap pharmaceutical giant like Sanofi, valued at more than $100 billion, abandoning a zero-revenue clinical trial asset is a neces", "url": "https://finance.yahoo.com/healthcare/articles/why-amlitelimab-setback-isn-t-232940996.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-10T23:29:40+00:00", "published_display": "10 Aug 2026 23:29", "sentiment": "positive", "sentiment_pct": 63, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.259, "duplicate_count": 1, "topics": ["Biotech", "Clinical Trials", "Earnings", "Earnings Report", "Fda Approval", "Institutional Investors"]}, {"title": "Nurix Therapeutics' STAT6 Degrader Likely to Receive Increased Recognition, RBC Says", "summary": "Nurix Therapeutics' (NRIX) STAT6 degrader NX-3911 is likely to receive increased recognition after advancing into clinical development under its collaboration with Sanofi (SNY), RBC Capital Markets said in a Monday research note.The investment firm said limited preclinical data Silver Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade now", "url": "https://finance.yahoo.com/healthcare/articles/nurix-therapeutics-apos-stat6-degrader-164414074.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-10T16:44:14+00:00", "published_display": "10 Aug 2026 16:44", "sentiment": "positive", "sentiment_pct": 61, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.153, "duplicate_count": 1, "topics": ["Clinical Trials", "Pharma"]}, {"title": "Novavax (NVAX) Is Up 8.6% After Beating Q2 Estimates And Expanding Big-Pharma Partnerships - What's Changed", "summary": "In early August 2026, Novavax reported Q2 2026 revenue of US$56.7 million, sharply lower than the prior year, and moved from net income to a net loss of US$53.39 million, translating into basic and diluted losses of US$0.32 per share from continuing operations. Alongside the weak year-on-year comparisons, Novavax beat analyst expectations for both revenue and earnings and highlighted progress on high-profile partnerships, including Sanofi and Pfizer, while also filing an US$82.47 million employee stock offering shelf registration. Now we'll examine how this mix of better-than-expected Q2 resul", "url": "https://finance.yahoo.com/healthcare/articles/novavax-nvax-8-6-beating-101004083.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-08T10:10:04+00:00", "published_display": "08 Aug 2026 10:10", "sentiment": "negative", "sentiment_pct": 24, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.122, "duplicate_count": 1, "topics": ["Dilution Risk", "Earnings", "Guidance", "Net Income", "Partnerships", "Share Price"]}], "industry": [], "sector": []}, "total_fetched": 6, "total_unique": 6, "total_relevant": 6, "pipeline_health": {"providers_attempted": 1, "providers_with_results": 1, "raw_articles": 6, "unique_stories": 6, "duplicates_removed": 0, "relevant_stories": 6, "current_evidence": 6, "direct_evidence": 6, "eodhd_articles": 6, "eodhd": {"configured": true, "status": "healthy", "calls_used": 40, "call_budget": 500, "budget_used_pct": 8.0, "requests_made": 8, "last_success_at": "2026-08-13T00:46:08.072252+00:00", "newest_seen_at": "2026-08-13T00:07:59+00:00", "rate_limit": 1200, "rate_remaining": 1198, "last_error": "", "mapped_mentions": 3604, "unmapped_mentions": 1784}, "status": "healthy"}, "sentiment_summary": {"positive": 4, "negative": 1, "neutral": 1, "score": 55, "raw_score": 57, "total": 6, "evidence_count": 6, "effective_articles": 5.49, "direct_story_count": 6, "industry_story_count": 0, "sector_story_count": 0, "story_count": 6, "source_count": 1, "source_concentration": 1.0, "direct_share": 100, "dispersion": 11, "confidence": 72, "evidence_status": "measured", "score_version": "evidence-v4", "newest_article_at": "2026-08-12T17:30:00+00:00", "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "regulatory", "primary_label": "Regulatory and legal", "confidence": 62, "events": [{"event": "regulatory", "label": "Regulatory and legal", "weight": 1.2, "count": 2}, {"event": "guidance", "label": "Guidance", "weight": 0.6, "count": 1}, {"event": "general", "label": "Market update", "weight": 0.6, "count": 1}, {"event": "analyst", "label": "Analyst action", "weight": 0.6, "count": 1}, {"event": "earnings", "label": "Earnings", "weight": 0.6, "count": 1}], "positive_events": 4, "negative_events": 1, "pipeline": {"providers_attempted": 1, "providers_with_results": 1, "raw_articles": 6, "unique_stories": 6, "duplicates_removed": 0, "relevant_stories": 6, "current_evidence": 6, "direct_evidence": 6, "eodhd_articles": 6, "eodhd": {"configured": true, "status": "healthy", "calls_used": 40, "call_budget": 500, "budget_used_pct": 8.0, "requests_made": 8, "last_success_at": "2026-08-13T00:46:08.072252+00:00", "newest_seen_at": "2026-08-13T00:07:59+00:00", "rate_limit": 1200, "rate_remaining": 1198, "last_error": "", "mapped_mentions": 3604, "unmapped_mentions": 1784}, "status": "healthy"}}, "market_context": {"has_market_context": true, "latest_close": 75.31, "latest_week": "2026-08-07", "one_week_move": 1.5, "four_week_move": -1.2, "twelve_week_move": 1.8, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 0.723109, "market_dynamics_buy_signal": false, "relative_strength": -9.125605, "fair_value_gap": -7.9, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "undecided", "expectation_probability": 53.9845, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "+1.5% over one week, -1.2% over four weeks, trend inactive, and near fair-value range."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 61, "badges": [], "opportunities": [], "risks": [], "event_label": "Regulatory and legal", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "finance.yahoo.com", "count": 6}], "tiers": [{"label": "Direct company coverage", "count": 6}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Regulatory and legal", "count": 2}, {"label": "Guidance", "count": 1}, {"label": "Market update", "count": 1}, {"label": "Analyst action", "count": 1}, {"label": "Earnings", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "55/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Evidence confidence", "value": "72/100", "tone": "positive", "text": "5.49 effective stories after overlap and weighting."}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Regulatory and legal", "tone": "neutral", "text": "62/100 classification confidence."}, {"label": "Company focus", "value": "6", "tone": "positive", "text": "100% of weighted evidence is company-specific."}, {"label": "Evidence agreement", "value": "11/100", "tone": "positive", "text": "lower dispersion means the independent stories agree more closely."}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+1.5% over one week, -1.2% over four weeks, trend inactive, and near fair-value range."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "[Latest] Global Whey Protein Market Size/Share Worth USD 26.04 Billion by 2034 at a 7.56% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)"}], "updated_at": "2026-08-13T00:50:57.437374+00:00", "detail_intelligence": {"headline": "Balanced read", "summary": "Balanced news tone is drawn from 6 fresh independent stories, including 6 company-specific items across 1 publishers.", "status": "measured", "metrics": [{"label": "Weighted tone", "value": 55, "display": "55", "tone": "neutral", "note": "Balanced news tone"}, {"label": "Evidence confidence", "value": 72, "display": "72", "tone": "positive", "note": "solid confidence"}, {"label": "Company focus", "value": 100, "display": "100%", "tone": "positive", "note": "6 direct stories"}, {"label": "Evidence agreement", "value": 89, "display": "89", "tone": "positive", "note": "11/100 dispersion"}], "confidence_drivers": [{"label": "Sample depth", "value": 69, "note": "5.49 effective stories"}, {"label": "Source breadth", "value": 20, "note": "1 independent publishers"}, {"label": "Direct relevance", "value": 100, "note": "company-specific evidence share"}, {"label": "Freshness", "value": 80, "note": "recency-weighted evidence"}, {"label": "Agreement", "value": 89, "note": "cross-story consistency"}, {"label": "Source independence", "value": 0, "note": "lower publisher concentration"}], "freshness": 80, "source_independence": 0, "timeline": [{"date": "2026-07-23", "label": "23 Jul", "count": 0, "score": null, "tone": "neutral", "x": 42.0, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-24", "label": "24 Jul", "count": 0, "score": null, "tone": "neutral", "x": 87.8, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-25", "label": "25 Jul", "count": 0, "score": null, "tone": "neutral", "x": 133.6, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-26", "label": "26 Jul", "count": 0, "score": null, "tone": "neutral", "x": 179.4, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-27", "label": "27 Jul", "count": 0, "score": null, "tone": "neutral", "x": 225.2, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-28", "label": "28 Jul", "count": 0, "score": null, "tone": "neutral", "x": 271.0, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-29", "label": "29 Jul", "count": 0, "score": null, "tone": "neutral", "x": 316.8, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-30", "label": "30 Jul", "count": 0, "score": null, "tone": "neutral", "x": 362.6, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-31", "label": "31 Jul", "count": 0, "score": null, "tone": "neutral", "x": 408.4, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-01", "label": "01 Aug", "count": 0, "score": null, "tone": "neutral", "x": 454.2, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-02", "label": "02 Aug", "count": 0, "score": null, "tone": "neutral", "x": 500.0, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-03", "label": "03 Aug", "count": 0, "score": null, "tone": "neutral", "x": 545.8, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-04", "label": "04 Aug", "count": 0, "score": null, "tone": "neutral", "x": 591.6, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-05", "label": "05 Aug", "count": 0, "score": null, "tone": "neutral", "x": 637.4, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-06", "label": "06 Aug", "count": 0, "score": null, "tone": "neutral", "x": 683.2, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-07", "label": "07 Aug", "count": 0, "score": null, "tone": "neutral", "x": 729.0, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-08", "label": "08 Aug", "count": 1, "score": 24, "tone": "negative", "x": 774.8, "y": 182.3, "volume_height": 17.3, "volume_y": 248.7}, {"date": "2026-08-09", "label": "09 Aug", "count": 0, "score": null, "tone": "neutral", "x": 820.6, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-10", "label": "10 Aug", "count": 2, "score": 62, "tone": "positive", "x": 866.4, "y": 113.2, "volume_height": 34.7, "volume_y": 231.3}, {"date": "2026-08-11", "label": "11 Aug", "count": 0, "score": null, "tone": "neutral", "x": 912.2, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-12", "label": "12 Aug", "count": 3, "score": 60, "tone": "positive", "x": 958.0, "y": 116.8, "volume_height": 52.0, "volume_y": 214.0}], "timeline_points": "774.8,182.3 866.4,113.2 958.0,116.8", "timeline_has_signal": true, "timeline_start": "23 Jul", "timeline_mid": "02 Aug", "timeline_end": "12 Aug", "momentum": {"label": "Improving", "tone": "positive", "recent_score": 61, "prior_score": 24, "delta": 37, "recent_count": 5, "prior_count": 1, "volume_delta": 4}, "freshness_buckets": [{"label": "Last 24 hours", "count": 3, "share": 50}, {"label": "1 to 3 days", "count": 2, "share": 33}, {"label": "4 to 7 days", "count": 1, "share": 17}, {"label": "8 to 30 days", "count": 0, "share": 0}], "source_profile": [{"label": "finance.yahoo.com", "count": 6, "share": 100, "score": 57, "tone": "neutral"}], "event_profile": [{"label": "Regulatory and legal", "count": 2, "share": 33, "score": 59, "tone": "positive"}, {"label": "Earnings", "count": 1, "share": 17, "score": 24, "tone": "negative"}, {"label": "Market update", "count": 1, "share": 17, "score": 65, "tone": "positive"}, {"label": "Guidance", "count": 1, "share": 17, "score": 61, "tone": "positive"}, {"label": "Analyst action", "count": 1, "share": 17, "score": 61, "tone": "positive"}], "topics": [{"label": "Clinical Trials", "count": 4, "share": 67}, {"label": "Biotech", "count": 3, "share": 50}, {"label": "Partnerships", "count": 2, "share": 33}, {"label": "Earnings", "count": 2, "share": 33}, {"label": "Sports Nutrition", "count": 1, "share": 17}, {"label": "Share Price", "count": 1, "share": 17}, {"label": "Pharma", "count": 1, "share": 17}, {"label": "Oncology", "count": 1, "share": 17}, {"label": "Net Income", "count": 1, "share": 17}, {"label": "Market Research Reports", "count": 1, "share": 17}], "supporting": [{"label": "Direct evidence", "text": "6 current stories are mapped specifically to SAN."}, {"label": "Narrative agreement", "text": "Cross-story agreement is 89/100, indicating a comparatively coherent tape."}], "tempering": [{"label": "Source breadth", "text": "Only 1 publisher currently contribute to the measured read."}], "supporting_heading": "What supports the read", "tempering_heading": "What tempers the read", "latest_observation": {"title": "[Latest] Global Whey Protein Market Size/Share Worth USD 26.04 Billion by 2034 at a 7.56% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)", "summary": "Custom Market Insights [220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Whey Protein Market size & share revenue was valued at approximately USD 12.58 Billion in 2024 and is expected to reach USD 13.52 Billion in 2025 and is expected to reach around USD 26.04 Billion by 2034, at a CAGR of 7.56% between 2025 and 2034. The key market players listed in the report with their sales, revenues and strategies are Abbott, Alpavit, Arla Foods, Carbery Group, Davisco Foods International, Inc., Fonterra Co-operative Group Lt", "url": "https://finance.yahoo.com/markets/commodities/articles/latest-global-whey-protein-market-173000212.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-12T17:30:00+00:00", "published_display": "12 Aug 2026 17:30", "sentiment": "positive", "sentiment_pct": 61, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.297, "duplicate_count": 1, "topics": ["Dietary Supplements", "E Commerce", "Functional Foods", "Growth Rate", "Market Research Reports", "Sports Nutrition"]}, "article_count": 6, "updated_at": "2026-08-12T23:39:56.993844+00:00"}, "price_sentiment_path": {"available": true, "price_points": [{"x": 42.0, "y": 166.9, "label": "13 Feb 2026", "close": 73.51, "index": 100.0}, {"x": 78.6, "y": 128.1, "label": "20 Feb 2026", "close": 75.37, "index": 102.5}, {"x": 115.2, "y": 76.3, "label": "27 Feb 2026", "close": 77.85, "index": 105.9}, {"x": 151.8, "y": 191.3, "label": "06 Mar 2026", "close": 72.35, "index": 98.4}, {"x": 188.5, "y": 191.3, "label": "13 Mar 2026", "close": 72.35, "index": 98.4}, {"x": 225.1, "y": 163.6, "label": "20 Mar 2026", "close": 73.67, "index": 100.2}, {"x": 261.7, "y": 80.4, "label": "27 Mar 2026", "close": 77.65, "index": 105.6}, {"x": 298.3, "y": 68.7, "label": "03 Apr 2026", "close": 78.21, "index": 106.4}, {"x": 334.9, "y": 116.0, "label": "10 Apr 2026", "close": 75.94, "index": 103.3}, {"x": 371.5, "y": 79.8, "label": "17 Apr 2026", "close": 77.68, "index": 105.7}, {"x": 408.2, "y": 118.2, "label": "24 Apr 2026", "close": 75.84, "index": 103.2}, {"x": 444.8, "y": 123.4, "label": "01 May 2026", "close": 75.59, "index": 102.8}, {"x": 481.4, "y": 175.5, "label": "08 May 2026", "close": 73.1, "index": 99.4}, {"x": 518.0, "y": 157.5, "label": "15 May 2026", "close": 73.96, "index": 100.6}, {"x": 554.6, "y": 96.5, "label": "22 May 2026", "close": 76.88, "index": 104.6}, {"x": 591.2, "y": 129.7, "label": "29 May 2026", "close": 75.29, "index": 102.4}, {"x": 627.8, "y": 74.1, "label": "05 Jun 2026", "close": 77.95, "index": 106.0}, {"x": 664.5, "y": 102.5, "label": "12 Jun 2026", "close": 76.59, "index": 104.2}, {"x": 701.1, "y": 153.8, "label": "19 Jun 2026", "close": 74.14, "index": 100.9}, {"x": 737.7, "y": 134.3, "label": "26 Jun 2026", "close": 75.07, "index": 102.1}, {"x": 774.3, "y": 118.8, "label": "03 Jul 2026", "close": 75.81, "index": 103.1}, {"x": 810.9, "y": 110.1, "label": "10 Jul 2026", "close": 76.23, "index": 103.7}, {"x": 847.5, "y": 86.9, "label": "17 Jul 2026", "close": 77.34, "index": 105.2}, {"x": 884.2, "y": 114.2, "label": "24 Jul 2026", "close": 76.03, "index": 103.4}, {"x": 920.8, "y": 153.1, "label": "31 Jul 2026", "close": 74.17, "index": 100.9}, {"x": 957.4, "y": 129.3, "label": "07 Aug 2026", "close": 75.31, "index": 102.4}], "sentiment_points": [{"x": 715.4, "y": 137.4, "label": "21 Jun 2026", "score": 46}, {"x": 720.8, "y": 137.4, "label": "22 Jun 2026", "score": 46}, {"x": 721.2, "y": 137.4, "label": "22 Jun 2026", "score": 46}, {"x": 726.8, "y": 137.4, "label": "23 Jun 2026", "score": 46}, {"x": 732.6, "y": 137.4, "label": "25 Jun 2026", "score": 46}, {"x": 739.1, "y": 137.4, "label": "26 Jun 2026", "score": 46}, {"x": 746.3, "y": 133.7, "label": "27 Jun 2026", "score": 48}, {"x": 751.9, "y": 137.4, "label": "28 Jun 2026", "score": 46}, {"x": 763.4, "y": 133.7, "label": "30 Jun 2026", "score": 48}, {"x": 773.0, "y": 133.7, "label": "02 Jul 2026", "score": 48}, {"x": 773.4, "y": 133.7, "label": "02 Jul 2026", "score": 48}, {"x": 798.0, "y": 133.7, "label": "07 Jul 2026", "score": 48}, {"x": 806.8, "y": 133.7, "label": "09 Jul 2026", "score": 48}, {"x": 821.1, "y": 133.7, "label": "11 Jul 2026", "score": 48}, {"x": 821.7, "y": 133.7, "label": "12 Jul 2026", "score": 48}, {"x": 823.5, "y": 133.7, "label": "12 Jul 2026", "score": 48}, {"x": 841.8, "y": 133.7, "label": "15 Jul 2026", "score": 48}, {"x": 856.2, "y": 133.7, "label": "18 Jul 2026", "score": 48}, {"x": 862.0, "y": 131.8, "label": "19 Jul 2026", "score": 49}, {"x": 877.6, "y": 131.8, "label": "22 Jul 2026", "score": 49}, {"x": 877.8, "y": 131.8, "label": "22 Jul 2026", "score": 49}, {"x": 880.5, "y": 131.8, "label": "23 Jul 2026", "score": 49}, {"x": 881.2, "y": 131.8, "label": "23 Jul 2026", "score": 49}, {"x": 882.7, "y": 130.0, "label": "23 Jul 2026", "score": 50}, {"x": 888.4, "y": 130.0, "label": "24 Jul 2026", "score": 50}, {"x": 907.7, "y": 133.7, "label": "28 Jul 2026", "score": 48}, {"x": 920.3, "y": 135.5, "label": "30 Jul 2026", "score": 47}, {"x": 934.6, "y": 131.8, "label": "02 Aug 2026", "score": 49}, {"x": 944.4, "y": 133.7, "label": "04 Aug 2026", "score": 48}, {"x": 958.0, "y": 133.7, "label": "07 Aug 2026", "score": 48}], "price_path": "42.0,166.9 78.6,128.1 115.2,76.3 151.8,191.3 188.5,191.3 225.1,163.6 261.7,80.4 298.3,68.7 334.9,116.0 371.5,79.8 408.2,118.2 444.8,123.4 481.4,175.5 518.0,157.5 554.6,96.5 591.2,129.7 627.8,74.1 664.5,102.5 701.1,153.8 737.7,134.3 774.3,118.8 810.9,110.1 847.5,86.9 884.2,114.2 920.8,153.1 957.4,129.3", "sentiment_path": "715.4,137.4 720.8,137.4 721.2,137.4 726.8,137.4 732.6,137.4 739.1,137.4 746.3,133.7 751.9,137.4 763.4,133.7 773.0,133.7 773.4,133.7 798.0,133.7 806.8,133.7 821.1,133.7 821.7,133.7 823.5,133.7 841.8,133.7 856.2,133.7 862.0,131.8 877.6,131.8 877.8,131.8 880.5,131.8 881.2,131.8 882.7,130.0 888.4,130.0 907.7,133.7 920.3,135.5 934.6,131.8 944.4,133.7 958.0,133.7", "price_change": 2.4, "sentiment_change": 2, "latest_close": 75.31, "start_label": "13 Feb", "mid_label": "15 May", "end_label": "07 Aug"}, "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}